NO20054336L - Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer - Google Patents

Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer

Info

Publication number
NO20054336L
NO20054336L NO20054336A NO20054336A NO20054336L NO 20054336 L NO20054336 L NO 20054336L NO 20054336 A NO20054336 A NO 20054336A NO 20054336 A NO20054336 A NO 20054336A NO 20054336 L NO20054336 L NO 20054336L
Authority
NO
Norway
Prior art keywords
component
asthma
allergic
inflammatory diseases
methods
Prior art date
Application number
NO20054336A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054336D0 (no
Inventor
Michael R Bowman
Debra Ellis
Maximillian T Follettie
Aaron Winkler
Cara Williams
Heng Chen
Wei Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054336D0 publication Critical patent/NO20054336D0/no
Publication of NO20054336L publication Critical patent/NO20054336L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
NO20054336A 2003-03-04 2005-09-20 Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer NO20054336L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45139603P 2003-03-04 2003-03-04
US47587003P 2003-06-05 2003-06-05
PCT/US2004/006470 WO2005003164A2 (en) 2003-03-04 2004-03-04 Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases

Publications (2)

Publication Number Publication Date
NO20054336D0 NO20054336D0 (no) 2005-09-20
NO20054336L true NO20054336L (no) 2005-12-02

Family

ID=33567303

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054336A NO20054336L (no) 2003-03-04 2005-09-20 Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer

Country Status (11)

Country Link
US (2) US20040234517A1 (es)
EP (1) EP1599587A2 (es)
JP (1) JP2007537984A (es)
KR (1) KR20050106483A (es)
AU (1) AU2004253846A1 (es)
BR (1) BRPI0408004A (es)
CA (1) CA2517684A1 (es)
MX (1) MXPA05009251A (es)
NO (1) NO20054336L (es)
RU (2) RU2005130636A (es)
WO (1) WO2005003164A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005620A2 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
EP1913401A4 (en) * 2005-08-03 2009-11-18 Astrazeneca Ab METHOD FOR IDENTIFYING AN AGENT THAT MODULATES TRANSPORTATION OF ARGININE IN A CHONDROCYTE
EP1933624A4 (en) * 2005-10-11 2009-09-16 Univ Washington COMPOSITIONS AND METHOD FOR THE TREATMENT OF HYPERSEKRETION OF RESPIRATORY WAYS
US20100056480A1 (en) * 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
US20090155784A1 (en) * 2007-01-22 2009-06-18 Wyeth Assessment of asthma and allergen-dependent gene expression
ATE504296T1 (de) * 2007-03-06 2011-04-15 Rachid Ennamany Zusammensetzung auf basis von rutin und l-lysin
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
JP2012520469A (ja) 2009-03-12 2012-09-06 キャンサー・プリヴェンション・アンド・キュア，リミテッド 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット
GB201007556D0 (en) * 2010-05-06 2010-06-23 Wetenschappelijk En Tech Ct Va Methods and compositions for textile layers and coatings
EP2576783B1 (en) * 2010-05-26 2017-11-29 CuRNA, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
JP6023705B2 (ja) * 2010-06-23 2016-11-09 カッパーアールエヌエー，インコーポレイテッド ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
WO2015165374A1 (en) 2014-04-29 2015-11-05 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase i
WO2018187496A2 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
CA3190519A1 (en) * 2020-08-26 2022-03-03 Cila Therapeutics Inc. Inhalable therapeutic agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
JP2547714B2 (ja) * 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US6784163B1 (en) * 1990-04-13 2004-08-31 Macleod Carol L. Inhibition of cationic amino acid transporter protein and uses thereof
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
GB9509757D0 (en) * 1995-05-13 1995-07-05 Ilford Ltd Toning of photographic print material
JP2004506683A (ja) * 2000-08-24 2004-03-04 ザ　リージェンツ　オブ　ザ　ユニバーシティ　オブ　カリフォルニア α−ジフルオロメチルオルニチン（ＤＦＭＯ）は、ヒト前立腺におけるポリアミンレベルを抑制する
MXPA04008286A (es) * 2002-03-01 2005-07-27 Children S Hospital And Region Tratamiento para asma o alergias.
AU2003218099A1 (en) * 2002-03-12 2003-09-29 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
EP2397128A1 (en) * 2003-02-14 2011-12-21 Children's Hospital & Research Center at Oakland Use of L-arginine optionally combined with magnesium for the treatment of sickle cell disease and/or pulmonary hypertension

Also Published As

Publication number Publication date
KR20050106483A (ko) 2005-11-09
NO20054336D0 (no) 2005-09-20
US20090156537A1 (en) 2009-06-18
WO2005003164A2 (en) 2005-01-13
AU2004253846A1 (en) 2005-01-13
CA2517684A1 (en) 2005-01-13
WO2005003164A3 (en) 2005-05-12
BRPI0408004A (pt) 2006-02-14
JP2007537984A (ja) 2007-12-27
US20040234517A1 (en) 2004-11-25
WO2005003164A9 (en) 2006-07-20
EP1599587A2 (en) 2005-11-30
RU2005130636A (ru) 2006-05-10
MXPA05009251A (es) 2005-10-19
RU2008145510A (ru) 2010-05-27

Similar Documents

Publication Publication Date Title
NO20054336L (no) Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer
Yuan et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters
Chang et al. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
Guimarães et al. Implications of SARS-Cov-2 infection on eNOS and iNOS activity: Consequences for the respiratory and vascular systems
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
NO20084005L (no) Aminderivater
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
WO2011056985A3 (en) Substituted heterocyclic compounds
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
UY32062A (es) Inhibidores de beta-secretasa
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
IL195030A (en) IV dpp inhibitor assemblies
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2008141731A3 (en) Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20054957L (no) Subtituerte karboksylsyrer
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
NO20083690L (no) Hydantoin baserte kinase-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application